Donald Biek

1.2k total citations
26 papers, 966 citations indexed

About

Donald Biek is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Donald Biek has authored 26 papers receiving a total of 966 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Pharmacology and 10 papers in Epidemiology. Recurrent topics in Donald Biek's work include Antimicrobial Resistance in Staphylococcus (17 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Pneumonia and Respiratory Infections (8 papers). Donald Biek is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (17 papers), Antibiotics Pharmacokinetics and Efficacy (15 papers) and Pneumonia and Respiratory Infections (8 papers). Donald Biek collaborates with scholars based in United States, France and Australia. Donald Biek's co-authors include Patrick K. Martin, Dongxu Sun, Molly B. Schmid, Tong Li, Yigong Ge, Ian A. Critchley, Daniel F. Sahm, George H. Talbot, Ronald N. Jones and David Lane and has published in prestigious journals such as PLoS ONE, Journal of Molecular Biology and Journal of Bacteriology.

In The Last Decade

Donald Biek

26 papers receiving 938 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald Biek United States	17	534	339	287	284	212	26	966
Steve N. Leonard United States	11	499 0.9×	458 1.4×	162 0.6×	114 0.4×	229 1.1×	11	937
Lynne Garrity-Ryan United States	15	323 0.6×	291 0.9×	244 0.9×	312 1.1×	473 2.2×	25	1.1k
Tatiana Bogdanovich United States	17	391 0.7×	237 0.7×	278 1.0×	275 1.0×	522 2.5×	27	1.1k
Silke Besier Germany	16	502 0.9×	436 1.3×	100 0.3×	182 0.6×	304 1.4×	28	985
Guilène Barnaud France	14	240 0.4×	298 0.9×	137 0.5×	244 0.9×	584 2.8×	23	1.1k
A Strässle Switzerland	14	802 1.5×	439 1.3×	97 0.3×	226 0.8×	188 0.9×	20	980
Klaudia Kosowska-Shick United States	19	708 1.3×	380 1.1×	325 1.1×	278 1.0×	320 1.5×	35	1.1k
Steve H. Marshall United States	13	373 0.7×	227 0.7×	209 0.7×	210 0.7×	579 2.7×	18	930
F. Sabatelli United States	8	575 1.1×	214 0.6×	188 0.7×	468 1.6×	417 2.0×	15	1.1k
Louis Garry France	16	344 0.6×	175 0.5×	99 0.3×	183 0.6×	218 1.0×	31	769

Countries citing papers authored by Donald Biek

Since Specialization

Citations

This map shows the geographic impact of Donald Biek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Biek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Biek more than expected).

Fields of papers citing papers by Donald Biek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Biek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Biek. The network helps show where Donald Biek may publish in the future.

Co-authorship network of co-authors of Donald Biek

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Biek. A scholar is included among the top collaborators of Donald Biek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Biek. Donald Biek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lemmon, M. Megan, et al.. (2021). In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens. The Journal of Antibiotics. 74(12). 884–892. 11 indexed citations

Keepers, Tiffany R., Marcela Gómez, Chris Celeri, et al.. (2017). Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. Infectious Diseases and Therapy. 6(2). 233–243. 19 indexed citations

Cannavino, Christopher, Rodrigo E. Mendes, Hélio S. Sader, et al.. (2016). Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. The Pediatric Infectious Disease Journal. 35(7). 813–815. 14 indexed citations

Keepers, Tiffany R., Marcela Gómez, Donald Biek, Ian A. Critchley, & Kevin M. Krause. (2015). Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations. International Scholarly Research Notices. 2015. 1–6. 3 indexed citations

Biek, Donald, et al.. (2014). Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections. Expert Review of Clinical Pharmacology. 7(2). 123–135. 5 indexed citations

Mendes, Rodrigo E., Andrew J. Costello, Michael R. Jacobs, et al.. (2014). Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagnostic Microbiology and Infectious Disease. 80(1). 19–25. 42 indexed citations

Tong, Steven Y. C., Yurong Zhang, Supaporn Lamlertthon, et al.. (2012). Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome for Staphylococcus aureus Skin Infections: Evaluation from the CANVAS Studies. PLoS ONE. 7(5). e37212–e37212. 27 indexed citations

Steed, Molly E., et al.. (2012). Evaluation of Ceftaroline Activity versus Ceftriaxone against Clinical Isolates of Streptococcus pneumoniae with Various Susceptibilities to Cephalosporins in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy. 56(5). 2691–2695. 10 indexed citations

Friedland, H. David, Tanya O’Neal, Donald Biek, et al.. (2012). CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy. 56(5). 2231–2236. 57 indexed citations

10.

Bhalodi, Amira A., Jared L. Crandon, Donald Biek, & David P. Nicolau. (2012). Efficacy of Ceftaroline Fosamil in a Staphylococcal Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy. 56(12). 6160–6165. 31 indexed citations

11.

Croisier, Delphine, Lionel Piroth, Pierre‐Emmanuel Charles, et al.. (2011). Ceftaroline versus Ceftriaxone in a Highly Penicillin-Resistant Pneumococcal Pneumonia Rabbit Model Using Simulated Human Dosing. Antimicrobial Agents and Chemotherapy. 55(7). 3557–3563. 27 indexed citations

12.

Richter, Sandra S., Kristopher P. Heilmann, Cassie L. Dohrn, et al.. (2011). Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009. Antimicrobial Agents and Chemotherapy. 55(9). 4154–4160. 56 indexed citations

13.

Jacobs, Michael R., Caryn E. Good, Anne Windau, et al.. (2010). Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy. 54(6). 2716–2719. 61 indexed citations

14.

Jacobs, Michael R., Caryn E. Good, Saralee Bajaksouzian, Donald Biek, & Ian A. Critchley. (2010). Serotypes And Antimicrobial Susceptibility Of Streptococcus Pneumoniae Isolates From FOCUS 1 And 2, Two International Trials Of Ceftaroline In Patients Hospitalized For Community-acquired Bacterial Pneumonia. A5482–A5482. 1 indexed citations

15.

Jacqueline, Cédric, J. Caillon, V. Le Mabecque, et al.. (2009). In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and Vancomycin. Antimicrobial Agents and Chemotherapy. 53(12). 5300–5302. 24 indexed citations

16.

Edgar, Rotem, Donald Biek, & Michael B. Yarmolinsky. (2005). P1 plasmid partition: in vivo evidence for the ParA‐ and ParB‐mediated formation of an anchored parS complex in the absence of a partner parS. Molecular Microbiology. 59(1). 276–287. 8 indexed citations

17.

Martin, Patrick K., Tong Li, Dongxu Sun, Donald Biek, & Molly B. Schmid. (1999). Role in Cell Permeability of an Essential Two-Component System inStaphylococcus aureus. Journal of Bacteriology. 181(12). 3666–3673. 215 indexed citations

18.

Lane, David, et al.. (1999). The F plasmid centromere, sopC , is required for full repression of the sopAB operon 1 1Edited by I. B. Holland. Journal of Molecular Biology. 290(3). 627–638. 44 indexed citations

19.

Biek, Donald, et al.. (1995). A versatile low-copy-number cloning vector derived from plasmid F. Gene. 164(1). 55–58. 30 indexed citations

20.

Biek, Donald, et al.. (1995). Partition Functions of Mini-F Affect Plasmid DNA Topology inEscherichia coli. Journal of Molecular Biology. 246(3). 388–400. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact